ENTA
Enanta Pharmaceuticals, Inc.
ENTA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
ENTA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
ENTA's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
ENTA PE Valuation
ENTA has no meaningful PE right now: it lost money over the past year.
ENTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect ENTA's losses to shrink, with revenue declining.
ENTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.42 | +$1.90 |
| Q1 2026 | -$2.60 | +$1.94 |
| Q4 2025 | -$3.21 | +$1.74 |
| Q3 2025 | -$3.84 | +$1.64 |
| Q2 2025 | -$4.32 | +$1.14 |
| Q1 2025 | -$4.54 | +$1.71 |
| Q4 2024 | -$4.95 | +$1.62 |
| Q3 2024 | -$5.48 | +$0.90 |
ENTA is still losing money, but far less than before: $2.42 per share over the past year, against $6.57 at its worst in late 2023.
ENTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $14.4M | -22% |
| Q1 2026 | $17.2M | +15% |
| Q4 2025 | $18.6M | +9.8% |
| Q3 2025 | $15.1M | +3.5% |
| Q2 2025 | $18.3M | +1.9% |
| Q1 2025 | $14.9M | -12% |
| Q4 2024 | $17M | -5.8% |
| Q3 2024 | $14.6M | -23% |
ENTA's revenue fell from its 2019 peak and has held roughly level since: $14M last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -120% | -17 points |
| Q1 2026 | -69% | +95 points |
| Q4 2025 | -60% | +78 points |
| Q3 2025 | -122% | +83 points |
| Q2 2025 | -103% | +31 points |
| Q1 2025 | -164% | +28 points |
| Q4 2024 | -139% | +55 points |
| Q3 2024 | -204% | -41 points |
ENTA's operating margin was −120% last quarter, down 17 points from the same quarter a year ago.
ENTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10M | -158% |
| Q1 2026 | -$7.2M | +$8.9M |
| Q4 2025 | -$11.8M | +$13.7M |
| Q3 2025 | -$7.9M | +$11.4M |
| Q2 2025 | $17.4M | +$38.7M |
| Q1 2025 | -$16M | +$14.2M |
| Q4 2024 | -$25.5M | +$229K |
| Q3 2024 | -$19.4M | +$3.6M |
ENTA has burned cash in almost every quarter: −$37M over the past year, against −$44M the year before.
ENTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +50K shares |
| 1 year | +36% | +7.7M shares |
| 3 years | +40% | +8.4M shares |
| 5 years | +45% | +9.1M shares |
ENTA has 29M diluted shares, up 36% from a year ago.
ENTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -5.0x | Net Cash |
| Q4 2019 | -1.1x | Net Cash |
| Q3 2019 | -1.3x | Net Cash |
ENTA has more cash than debt.
ENTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 14.2 | Oversold |
ENTA's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
ENTA PE vs Healthcare Sector
| Metric | ENTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENTA has no meaningful PE right now: it lost money over the past year.
ENTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.6 | 3.6% below |
| 20 week MA | $12.7 | 12% below |
| 50 week MA | $13.3 | 15% below |
| 100 week MA | $10.4 | 7.8% above |
| 200 week MA | $14.5 | 23% below |
ENTA's trend is mixed: it's above one of its five weekly moving averages, and 23% below its 200-week average.
ENTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $42.9 | -31% |
| 2021 | $42.9 | $76.4 | +78% |
| 2022 | $76.4 | $47.1 | -38% |
| 2023 | $47.1 | $9.41 | -80% |
| 2024 | $9.41 | $6.01 | -36% |
| 2025 | $6.01 | $16.9 | +180% |
| 2026 YTD | $16.9 | $11.2 | -34% |
ENTA's yearly returns have swung widely, from +180% in 2025 to −80% in 2023. It's down 34% so far in 2026.